Calamos Advisors LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 45 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2021$4,535,000
+0.4%
5,000,0000.0%0.02%
-4.8%
Q2 2021$4,519,000
+9.3%
5,000,0000.0%0.02%
-8.7%
Q1 2021$4,136,000
+4.0%
5,000,0000.0%0.02%0.0%
Q4 2020$3,977,000
-1.5%
5,000,0000.0%0.02%
-11.5%
Q3 2020$4,037,000
+7.3%
5,000,0000.0%0.03%
-3.7%
Q2 2020$3,763,000
-7.6%
5,000,0000.0%0.03%
-15.6%
Q1 2020$4,072,000
-19.3%
5,000,0000.0%0.03%
+28.0%
Q4 2019$5,047,000
+17.3%
5,000,0000.0%0.02%
+8.7%
Q3 2019$4,301,000
-3.5%
5,000,0000.0%0.02%
-8.0%
Q2 2019$4,456,000
-10.2%
5,000,0000.0%0.02%
-19.4%
Q1 2019$4,960,000
+7.3%
5,000,0000.0%0.03%0.0%
Q4 2018$4,624,000
-8.3%
5,000,0000.0%0.03%
+10.7%
Q3 2018$5,044,000
+14.7%
5,000,0000.0%0.03%
+3.7%
Q2 2018$4,396,000
+8.9%
5,000,0000.0%0.03%
+3.8%
Q1 2018$4,038,000
+0.1%
5,000,0000.0%0.03%
+23.8%
Q4 2017$4,033,000
+3.4%
5,000,0000.0%0.02%
-30.0%
Q3 2017$3,900,000
-20.3%
5,000,0000.0%0.03%
-16.7%
Q2 2017$4,895,000
+5.0%
5,000,0000.0%0.04%
-2.7%
Q1 2017$4,660,000
+4.3%
5,000,0000.0%0.04%
+2.8%
Q4 2016$4,468,000
-20.3%
5,000,0000.0%0.04%
-10.0%
Q3 2016$5,603,0005,000,0000.04%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2018
NameSharesValueWeighting ↓
Worth Venture Partners, LLC 5,324,000$4,995,0003.78%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$53,020,0002.12%
DLD Asset Management, LP 32,500,000$30,048,0002.06%
Castle Creek Arbitrage, LLC 4,504,000$4,161,0001.43%
TENOR CAPITAL MANAGEMENT Co., L.P. 10,000,000$9,372,0000.62%
Graham Capital Management, L.P. 14,636,000$13,509,0000.60%
OAKTREE CAPITAL MANAGEMENT LP 64,452,000$59,704,0000.54%
Context Capital Management, LLC 1,000,000$926,0000.52%
ADVENT CAPITAL MANAGEMENT /DE/ 23,118,000$21,341,0000.52%
WOLVERINE ASSET MANAGEMENT LLC 18,583,000$17,322,0000.21%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders